Waldenström’s Macroglobulinemia [electronic resource] / edited by Véronique Leblond, Steve Treon, Meletios Dimoploulos.

Cham : Springer International Publishing : Imprint: Springer, 2017.
1 online resource (IX, 377 pages 28 illustrations, 15 illustrations in color.)
Contained In:
Springer eBooks

Location Notes Your Loan Policy


Local subjects:
Medicine & Public Health. (search)
Hematology. (search)
Immunology. (search)
Neurology. (search)
System Details:
text file PDF
This book sheds new light on clinical, biological and therapeutic data on the rare disease Waldenström’s Macroglobulinemia (WM) with the participation of widely-recognized experts, involved in this field. It represents the efforts of physicians, scientists and patients, all around the world, to better understand and cure this rare disease. Considerable advances in the diagnosis, treatment indications, response criteria, prognostic factors and treatment options have been made since Dr Jan Waldenström first reported this “new syndrome“ 70 years ago. Particularly instrumental in advancing of our understanding of WM have been the eight international workshops devoted to this disease. New, exciting molecular data have recently been reported, allowing us to revisit the oncogenic events leading to WM B-cell proliferation and to use newly available compounds targeting oncogenic pathways.
Preface: Tribute to J Waldenström
Part I: Tumor Cells and microenvironment
Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment
Waldenström’s Macroglobulinemia Immunophenotype
Predispositions and Origins of Waldenstrom Macroglobulinemia: Implications from Genetic Analysis
Cytogenetics in Waldenstr<öm Macroglobulinemia (WM)
Genetic and Signaling Abnormalities in Waldenström’s Macroglobulinemia
Molecular Pathways in Growth and Survival: Epigenomics
The Bone Marrow Microenvironment and Tumor Cells Interactions in Waldenström’s Macroglobulinemia
Waldenström’s Macroglobulinaemia: Immunosurveillance and the Immune Micro-environment
Part II: Epidemiology and Genetic Predisposition
Epidemiology of Waldenström Macroglobulinemia
Genetic Predisposition to Waldenström Macroglobulinemia
Immunoglobulin Type M Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS)
Part III: Clinical Features
Hyperviscosity Syndrome, Cold Agglutinin Hemolytic Anemia, and Cryoglobulinemia
Neuropathy in Waldenström’s Macroglobulinaemia
IgM Amyloidosis
The Bing-Neel Syndrome
Unusual Manifestations of IgM Monoclonal Gammopathies
Part IV: Laboratory Investigations
Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains
Part V: Response
Response Assessment in Waldenström’s Macroglobulinaemia
Part VI: Prognostic Factors
Risk Stratification in Waldenström Macroglobulinemia
Part VII: Treatment Options and Recommendations
Indications for Treatment of Waldenström’s Macroglobulinemia
Immunotherapy in Waldenström’s Macroglobulinemia
Immunomodulatory Agents and Proteasome Inhibitors in Waldenström’s Macroglobulinemia
Signal Inhibitors in Waldenström’s Macroglobulinemia
High-Dose Therapy and Haemopoietic Stem Cell Transplantation in Waldenström’s Macroglobulinaemia
Long-Term Toxicity of Therapy in Waldenström Macroglobulinemia
Treatment Recommendations in Waldenström Macroglobulinemia.
Leblond, Véronique. editor.
Treon, Steve, editor.
Dimopoulos, Meletios, editor.
SpringerLink (Online service)
Other format:
Printed edition:
Publisher Number:
10.1007/978-3-319-22584-5 doi
Access Restriction:
Restricted for use by site license.